Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Rating Reiterated by Goldman Sachs Group, Inc. (The)

Atara Biotherapeutics, Inc. (NASDAQ:ATRA)‘s stock had its “neutral” rating restated by equities research analysts at Goldman Sachs Group, Inc. (The) in a report released on Friday, October 6th, MarketBeat reports. They currently have a $20.00 price target on the biotechnology company’s stock. Goldman Sachs Group, Inc. (The)’s price target would indicate a potential upside of 39.86% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Jefferies Group LLC restated a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Canaccord Genuity reissued a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a research note on Monday, September 11th. ValuEngine raised shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Monday, August 28th. Finally, BidaskClub lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $24.40.

Atara Biotherapeutics (NASDAQ ATRA) opened at 14.30 on Friday. The stock’s 50 day moving average price is $15.57 and its 200-day moving average price is $15.28. The stock’s market cap is $436.99 million. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.05). Analysts anticipate that Atara Biotherapeutics will post ($3.91) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was reported by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/atara-biotherapeutics-inc-atra-receives-neutral-rating-from-goldman-sachs-group-inc-the/1703002.html.

In related news, EVP Christopher Haqq sold 7,604 shares of Atara Biotherapeutics stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $14.75, for a total value of $112,159.00. Following the completion of the sale, the executive vice president now owns 362,909 shares in the company, valued at approximately $5,352,907.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mitchall G. Clark sold 3,021 shares of Atara Biotherapeutics stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total transaction of $43,290.93. The disclosure for this sale can be found here. Insiders have sold a total of 60,509 shares of company stock valued at $906,736 in the last 90 days. Insiders own 16.20% of the company’s stock.

Several large investors have recently bought and sold shares of ATRA. Wells Fargo & Company MN grew its stake in shares of Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after acquiring an additional 4,791 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Atara Biotherapeutics by 5.3% in the first quarter. Bank of New York Mellon Corp now owns 120,097 shares of the biotechnology company’s stock worth $2,468,000 after acquiring an additional 6,069 shares in the last quarter. Swiss National Bank grew its stake in shares of Atara Biotherapeutics by 9.6% in the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock worth $588,000 after acquiring an additional 2,500 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in shares of Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after acquiring an additional 9,774 shares in the last quarter. Finally, American International Group Inc. grew its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 948 shares in the last quarter. Institutional investors and hedge funds own 82.95% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley


Leave a Reply

 
© 2006-2017 BBNS.